Summary & Overview
HCPCS J0775: Collagenase, Clostridium Histolyticum Injection, 0.01 mg
HCPCS Level II code J0775 denotes a unit of injection for collagenase, clostridium histolyticum at 0.01 mg. This code is used to bill for the pharmaceutical product itself when administered as an injectable biologic and is relevant for specialists and clinics that provide enzymatic collagen degradation treatments. Nationally, accurate coding for high-cost specialty injectables matters for claim adjudication, utilization tracking, and cost management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the drug formulation, typical sites of service where the product is administered, and the payer landscape relevant to coverage and billing. The publication outlines common billing considerations, benchmark touchpoints for unit-based reporting, and where to find policy updates affecting injectable specialty drugs.
The write-up provides actionable reference material for revenue cycle, clinical coding staff, and practice managers seeking clarity on how J0775 is described, where it is typically billed, and which major payers are commonly involved. Data not available in the input is explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code J0775 represents the drug injection collagenase, clostridium histolyticum, billed per unit of 0.01 mg. This code covers the pharmaceutical product formulation used for enzymatic collagen degradation in clinical indications where collagenase injection is an established therapy.
Service Type: Medication administration / injectable biologic
Typical Site of Service: Outpatient clinic or physician office, including ambulatory infusion or procedure suites where injections of specialty biologics are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient orthopedic or hand surgery clinic with a palpable, fixed cord and progressive digital flexion contracture consistent with Dupuytren contracture. The provider documents range-of-motion limitations, functional impairment (difficulty placing hand flat on a table or performing activities of daily living), and confirms the diagnosis by physical exam. After discussing nonsurgical options and obtaining informed consent, the clinician schedules an office-based injection of enzymatic collagenase (J0775, billed per 0.01 mg unit) to enzymatically weaken the cord. The service typically occurs in a clinic procedure room, ambulatory surgery center, or physician office. Local anesthesia may be provided; post-injection instructions include activity modification and follow-up for manipulation/extension of the affected finger in 24–72 hours. Documentation includes the specific product and units administered, injection sites, laterality, pre- and post-procedure neurovascular checks, informed consent, and plan for follow-up manipulation and rehabilitation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard claim | Use when no specific modifier applies and service is routine. |